ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Title:
ICON 9—an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy
Author:
Elyashiv, Osnat Ledermann, Jonathan Parmar, Gita Farrelly, Laura Counsell, Nicholas Feeney, Amanda El-Khouly, Fatima Macdonald, Ian Neto, Andreia Arthur-Darkwa, Esther Burnett, Eva Jayson, Gordon C Mileshkin, Linda Gourley, Charlie Nicum, Shibani
Appeared in:
International journal of gynecological cancer
Paging:
Volume 31 () nr. 1 pages 134-138
Year:
2021
Contents:
Publisher:
IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.